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Abstract 
 Adipose tissue has gained great attention during the last decade. It 
represents not only a depot for energy stores, but also releases 
adipocytokines  regulating energy disposal and can therefore be  considered 
from  therapeutic point of view.  Hypoadiponectemia is an independent 
threat for development of metabolic syndrome. When subjects treated with 
antidiabetic (Thiazolidinediones) and  antihypertensive (angiotensin receptor 
blocker) agents ,  the plasma concentration of adiponectin, the only 
component of adipocytokines,   directly proportional to plasma values of  
these drugs.  The prevalance of hypertension and T2DM  is mounting with 
unprecedented degree  in  both developing  and  advanced countries,  
therefore,  there is a dire need to find  safer and  economical therapeutic 
regimes for  the treatment of  these ailments, and  intensive research is also 
European Scientific Journal   August 2013  edition vol.9, No.24  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
101 
underway for this purpose. PPARγ serves as a common link in the actions of  
ADN, TZDs and ARBs when exerting their effects, and it is responsible for 
stimulation of adiponectin receptors,  thus ultimately enhancing  the  levels 
of adiponectin in plasma. This  review aims to  elucidate the role,  link and 
use of ARBs, ADN and TZDs  as a safer and convenient approach for the 
treatment of  these co-morbidities as a  unanimous or single remedy  from 
comparative  point of view.  
 
Keywords: Adiponectin (ADN), Thiazolidinediones (TZD), Angiotensin 
receptor blocker (ARB), Peroxisome proliferator–activated receptor (PPAR),  
Type 2 diabetes mellitus (T2DM) 
 
1.1 Introduction 
During the last ten years,  adipose tissue has entered into the sphere 
of cardiology. Adiponectin, an adipocytokine, is  involved  in regulating 
different physiological mechanisms in body. Consequently, the  idea of 
considering the adipose tissue  only as  a metabolic storehouse for energy  is 
outdated. In reality, it should be recognised as a vitally important endocrine 
organ which  produces biologically active compounds,  together known as 
adipokines. The  interaction between biological systems and  adipose tissue 
is attained through expression of bioactive mediators, known as 
adipocytokines. Adiponectin, resistin, leptin, interleukin 6, tumour necrosis 
factor and the inhibitor of plasmainogen activator-1 constitute  the major 
components of adipocytokines. 
Adiponectin is now  regarded as not only the secretory  factor from 
adipose tissue , but as an adipokine which  has  several beneficial effects on  
body.  Adipose complement is a related protein of 30 kDa,  with 247-amino 
acids  having  four differentiable domains. It  was identified  through  cDNA 
cloning of  the adipocyte mouse cell line 3T3-L1 and  was  referred to as 
Acrp30 by Scherer  (Scherer  et al., 1995), meanwhile in  1996,  while using 
the  adipocyte cell line, 3T3-F442A ,  isolated this protein  and  named  it 
AdipoQ  (Hu, Liang et al. 1996). The  other  names used for  adiponectin are  
apM1 (Maeda et al., 1996) and  GBP28 (Nakano et al.,1996). Thus this  
protein was  identified by different research groups  as a  protein  exclusively 
and  abundantly formed  in adipose tissue. 
The insulin-sensitizing adipokine, adiponectin is composed of N-
terminal collagenous and  C-terminal globular domain. It exists in three 
isoforms, globular, multimeric, and full  length  (Fantuzzi 2005).  It has also 
been  known as a  ‘fat burning molecule’, because of  its  ability to mobilise  
fatty acids to  muscle for their oxidation. This  is  of enormous concern,  as 
entry  of fatty acids in  to the liver will  decrease  and therefore  total 
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triglyceride content will also fall, which  ultimately  lead to an insulin-
sensitivit state  (Garaulet, et al., 2007). 
Plasma concentration  of  AND   ranges from 5 to 30 µg/µl, which 
makes 0.01%  of  total  plasma protein  (Gil-Campos, et al, 2004).  It exists 
as full-length AND  or globular domain  ADN   in  plasma (Fruebis, et al., 
2001 and  Yamauchi, et al., 2001, Kadowaki et al.,2005,  Kadowaki, et al., 
2006)  The most active form of ADN   is the  high-molecular-weight form, 
and it is related to insulin sensitivity. Both hexamers and  high-molecular-
weight oligomers circulate  in blood with  high concentrations of  nearly 
10 μg/ml  (Waki H et al., 2003), with  half- life in plasma up to 2.5 hrs 
(Hoffstedt,  et al., 2004).  It is apparent that for these  structures to have 
different actions  and  properties, and the ratio between  high molecular and  
low molecular weight structures, as compared to their respective 
concentrations, establish ADN  physiological activity (Pajvani et al., 2004). 
There is good evidence  that ADN  increases fatty acid oxidation  in skeletal  
muscle and  hepatic insulin action,  thus decreasing  glucose levels,  as  
revealed  from previous studies (Berg, et al., 2001 and  Tomas, et al., 2002). 
Production of  ADN takes place robustly by differentiated adipocytes, liver 
cells, and cardiomyocytes (Staiger  et al., 2003,  Piñeiro, et al., 2005 and  
Ding et al., 2007), thus   regulating   glucose and lipid breakdown  through 
increases in fatty acid oxidation and glucose uptake with  decrease of hepatic 
gluconeogenesis (and  Yamauchi  et al., 2002 and  Kadowaki  et al., 2005)   
Adiponectin  has  type 1 and  type 2 receptors.  In 2007,  Yamauchi   
isolated these two  related receptors by expression cloning from human 
skeletal muscle, and they share 67% of the gene sequencing. These receptors 
are activated by full length and globular ADN, and stimulate  enhanced 
adenosine monophosphate (AMP) kinase, leading to gluconeogenesis, 
PPAR-alpha ligand activity and β-oxidation with  searching for  reactive 
oxygen species (Yamauchi et al., 2007).  It is noteworthy  that AdipoR1 
binds to globular adiponectin, whereas AdipoR2 has affinity for full-length 
adiponectin (Kharroubi, et al., 2003 and Peake et al., 2005.  The expression 
of AdipoR1 is greater in skeletal muscles, whereas liver is enriched with 
AdipoR2 (Kadowaki and Ymauchi., 2005)  as shown in Fig 1.  Among these 
tissues,  AdipoR1 is important  for the  anti-inflammatory effects of  ADN  
on the walls of blood vessels and the cells lining. Several studies also 
revealed  that ADN acts as a  powerful anti-inflammatory adipocytokine 
(Yokota,  et al. 2000, Yamaguchi,  et al. 2005 and Thakur, et al., 2006 )  
which  also has anti-atherogenic  and anti-diabetic properties (Trujillo et al., 
2005), whereas the increased expression of  AdipoR2  is  believed to increase 
sensitivity of liver cells to ADN and thus augment the  anti-diabetic activity 
of ADN  (Sun, et al., 2006). In humans, the probability of  acquiring  insulin 
resistance, hyperinsulinaemia with an increased risk  for type 2 diabetes is 
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related to the  low serum concentration of adiponectin (Weyer, et al., 2001 
and Lindsay, et al., 2002). These receptors are up-regulated in fasting, 
whereas down regulation takes place following insulin administration 
(Tsuchida, et al., 2004). In addition, skeletal muscle and adipose tissue levels 
of AdipoR1 and AdipoR2 were found to be less in congenitally obese LepOb 
mice and humans where the chances of heart attack are elevated  (Ouchi, 
Kihara et al. 2000). Inukai and coleagues confirmed  the  inhibitory effect on 
obesity and  found  that  AdipoR1 expression was suppressed  in genetically 
diabetic obese and obese  mice (Inukai,  et al.,  2005). Plasma adiponectin 
concentrations are decreased in obese individuals (Hotta  et al., 2000, 
Okamoto, et al., 2002 and Ouchi et al., 2007), in coronary artery disease 
(Kumada, et al.,  2003)  and in  hypertensive individuals  (Iwashima  et al., 
2004).  By contrast, high ADN levels have been found in patients with 
essential hypertension, chronic and congestive heart failure ( Kistorp et al., 
2005 and George, et al., 2006). Its levels are positively  related to insulin 
sensitization, β-oxidation, and cardiovascular safety (Kadowaki etal., 2006 
and Scherer 2006 and), whereas hypoadiponectinemia, a risk for  
hypertension is independent of  insulin resistance and diabetes (Chow  et al., 
2007).  Male subjects have less of the HMW form as compared to females  
and in obese,  insulin-resistant subjects as  opposed to lean subjects and 
insulin-sensitive individuals. Human serum has generally the more abundant 
trimer form as compared to mouse adiponectin and the quantity of  HMW 
form selectively decreases in the circulation when obesity reduces 
adiponectin concentration  (Schraw, et al., 2008) 
It is also considered that hypoadiponectemia is an independent 
threat for development of metabolic syndrome  (Renaldi et al.,2009) and  
Diabetes mellitus  (Hara K et al.,2005).  In addition, the genomic locus 
encircling  human Acrp30 gene, 3q27, has  been recognized as a vulnerable 
locus for diabetes and  metabolic syndrome X (Comuzzie, et al., 2001). 
Studies  in rhesus monkeys demonstrate that  Acrp30 levels were inversely 
related  to body weight, fat content  and resting levels of insulin,  and 
declined   with progression toward the diabetic state (Hotta et al., 2001).  
Apart from these observations, treatment with ADN is responsible for  
reducing  extent of insulin resistance in lipoatrophic/obese mice (Yamauchi  
et al., 2001). 
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Fig.1 (Drawn from Marta Garaulet et al., 2007) Configurations of adiponectin 
 
1.2 Mode Of Acton Of Adiponectin 
There are  perplexing observations regarding the function  and  mode 
of action  of ADN, in relation to inflammation and insulin resistance 
(Garaulet, et al. 2007). In adipose tissue,  ADN  and TNF-α  jointly slow 
down each other's production (Maeda et al., 2001,  2002,  Fasshauer, et al., 
2002  and  Tomas, et al., 2002)  through activation of its specific receptors, 
AdipoR1 and AdipoR2 (Yamauchi, K et al. 2003).  For the insulin-
sensitizing action of ADN, Yamauchi observed that full-length ADN 
stimulated AMP-activated protein kinase (AMPK) phosphorylation in 
hepatocytes, whereas globular adiponectin did same in skeletal muscle and 
liver. The  blockade of AMPK activation repressed  the effects of  globular 
and full-length ADN, indicating that stimulation of fatty acid consumption 
and glucose utilization occured through an antidiabetic hormone known as  
AND (Berg  et al., 2001 and Yamauchi et al., 2002  and  ).  In another study 
Lodish  and  colleagues observed that the ADN globular domain improved 
glucose transport and muscle fat oxidation by  using acetyl-CoA carboxylase 
inhibition and AMPK activation (Tomas et al., 2002). It was also observed 
that ADN  increased energy consumption and fatty-acid combustion (fat 
burning molecule), through peroxisome proliferator activated receptor 
(PPARα) activation, which resulted in a decreased triglyceride content in 
skeletal muscle and  liver, and enhanced  insulin sensitivity (Yamauchi et al. 
2003). It has also been proposed that two pathways are involved in 
improving insulin resistance stimulated by PPARγ agonists 
thiazolidinediones (TZDs), rosiglitazone and  pioglitazone.  TZDs increase 
ADN levels, thereby improving insulin resistance, decreasing 
gluconeogenesis in  liver while increasing the AMPK activation (dependant  
pathway). Whereas, independent of ADN, TZDs reduce serum FFA levels, 
adipocyte size, as well as expression of resistin and TNF-α, which ultimately 
alters  the  insulin resistance of skeletal muscle (Yamauchi et al., 2001, Waki 
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et al., 2003, and  Kubota et al., 2006). Adiponectin  modulates  intracellular 
signaling pathways and stimulates PPARγ, AMPK  and MAPK in skeletal 
muscle and liver( Kelesidis et al., 2006). Even if ADN  activates  AMPK,  
there is  also evidence  which proves that  activation of AMPK through the 
AMP - mimetic and 5 – aminoimidazole – 4 - carboxamide ribonucleoside 
(AICAR) enhances ADN gene expression (Lihn et al., 2004) signifying a  
feedback circle between  AMPK and ADN in adipose tissue. Studies using 
spontaneously hypertensive rats revealed  an overexpression of ADN 
receptors (AdipoR1 and R2) and an impaired  downstream signalling of 
ADN  via the AMPK-ACC-CPT1 pathway in liver and skeletal muscle 
(Rodríguez, et al. 2008). Although adiponectin activates both AMPK and 
PPAR-α pathways and increase the expression of  AdipoR1 expression in 
coronary artery disease, nonetheless, in spite of increased muscle and 
circulating adiponectin levels, the PPAR-α/AMPK pathway is  deactivated,  
resulting  in decreased AdipoR1 expression for glucose metabolism and fatty 
acid, which favors a state of adiponectin resistance in coronary artery disease 
(Berendoncks et al., 2010).   
1.3 Peroxisome Proliferator - Activatedreceptor And Adiponectin  
Peroxisome proliferator–activated receptor (PPARs), is a subgroup  
of  a superfamily of  receptors  which are closely related to thyroid hormone 
(Rios-Vazquez et al., 2006). They are present in adipose tissue, vascular 
smooth cells, macrophages, vascular endothelial  and  renal  glomerular cells  
(Tontonoz et al., 1994, Sarafidis P.A et al., 2006 and Sarafidis et al., 2008), 
skeletal muscle ( Norris et al., 2003) and at high level in adipose tissue. So 
far three PPAR isoforms have been recognized as PPAR-α, PPAR-β (orδ) 
and PPAR-γ (Abbott et al., 2009). The nuclear hormone receptor peroxisome 
proliferator–activated receptor-γ  (PPARγ) serves as a factor  in the 
regulation of insulin sensitivity. PPARγ functions through activation of its 
ligands such as prostaglandins and thiazolidinediones/glitazones, as a  
transcriptional regulator of  genes involved in glucose and lipid metabolism, 
and through this means  may  ameliorate  type 2 diabetes (Picard et al., 
2002). The master regulator of adipogenesis, adipose PPARγ, is activated by  
thiazolidinediones (TZDs) which are used clinically to stimulate the action of 
insulin (Evans et al., 2004). PPARγ is highly  expressed  in adipose tissue, 
and its activation with TZDs changes the fat  landscape and adipocyte 
phenotype besides up-regulating the genes responsible for fatty acid 
metabolism  and triglyceride  storage  (Nedergaard et al., 2005, Sharma and 
Staels 2007).  PPARγ enhances adipose tissue modification besides fat mass 
accumulation brought about with an enhanced adipocyte differentiation by 
genes involved in lipid metabolism. Hydrolysis of triglyceride-rich 
lipoproteins results in fatty acids which are forwarded towards adipose 
tissue, hence glucose metabolism in the muscle increases, and  it  is linked 
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with an enhanced  expression of  genes responsible for glucose uptake and 
insulin signaling in adipose tissue and muscles, which ultimately could  
influence glucose processing. Therefore, PPARγ seems to care for cells 
against intracellular triglyceride buildup which is connected with type II 
diabetes (Picard et al., 2002). The  direct effect of PPAR-γ on adiponectin 
transcription is through PPAR-γ activation (Iwaki et al. 2003).  The insulin-
sensitising activities of PPARγ  agonists causes the decrease of  circulating 
levels of free fatty acids by inhibiting adipocyte lipolysis, apart from 
regulation of proteins which  modulates insulin sensitivity and lipid 
metabolism  ( Berger  2002,  Desvergne, et al. 2004,  Li and Glass 2004). 
The increased expression of AdipoR2 leads to an enhanced sensitivity of 
liver cells to adiponectin and thus  improvement in  anti-diabetic  activity of  
AND.  (Sun, et al. 2006)  The use of  PPAR-γ agonists results in an 
improvement in glycaemia in diabetic mice and is linked with an increase in 
circulating adiponectin  levels (Berg,  et al. 2001 and Bruce,  et al. 2005). 
PPARγ activation has been shown to stimulate adiponectin expression in 
adipocytes and to up-regulate ADN  plasma levels in animals and humans 
(Combs et al., 2002 and  Fasshauer et al., 2004) Therefore, PPARγ-
activating ligands improve adipose tissue function and thus help in averting 
the development of insulin resistance to diabetes along with endothelial 
dysfunction  in   atherosclerosis (Sharma and Staels 2007). Activation of 
PPARγ promotes the transcription of ADN and AdipoR1 (Chinetti et al., 
2004  and  Choi  et al., 2005),  whereas  activation of  AND  receptors have 
the potential for the treatment of endothelial dysfunction related to diabetes, 
obesity, and atherosclerosis (Zhang  et al.,  2009) 
1.4  Adiponectin And Thiazolidinediones 
“Diabetes mellitus” is defined by high blood glucose level. There is a 
failure of β-cells to produce insulin togather with a resistance of target 
tissues to the  action of insulin.  Impaired insulin secretion by the pancreas 
and  insulin resistance in peripheral tissues are the characteristics of Type II 
diabetes, which has increased dramaticaly over the last 50 years. There are  
about  285 million people worldwide in 2010 with this disease (Smyth and 
Heron., 2006). The increased  blood glucose level results in a range of  
serious complications which arises from the  persistently  elevated blood 
glucose levels. The major organ for glucose homeostasis is liver, in which 
insulin stops  gluconeogenesis  and stimulate  glycogen synthesis whereas  in  
muscle, insulin is responsible for  glucose uptake and synthesis of  glycogen; 
and  at white adipose tissue (WAT), where   glucose uptake is stimulated by 
insulin  (Chao et al., 2000)  
 Thiazolidinediones (TZDs) are currently being  used for the treatment 
of  T2DM (Bowen et al., 1991,  Nolan et al.,1994,  Saltiel.,  2001,  Rangwala  
and  Yki-Jarvinen  2004 ).  They are  categorized as  antidiabetic drugs, with  
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numerous effects on  CVD and lipid metabolism, through increasing levels 
of adiponectin. 
Although adipose tissue only accounts for 10% of the uptake of 
insulin- stimulated glucose, yet it plays an important  role in  whole-body 
glucose  homeostasis in adipose tissue, thus helping  adipose differentiation 
besides enhancing small adipocytes which are insulin sensitive (Okuno 
etal.,1998, Olefsky 2000, Evans 2004 and Rangwala 2004). The 
understanding that a fatty acid sensor like PPAR-γ  serves  as  an important 
regulator of glucose metabolism began  from the finding that the insulin-
sensitizing TZDs are potent agonists for PPAR, which are agonist ligands 
(Forman et al., 1995 and Lehmann et al., 1995), for the transcription factor 
and their antidiabetic effects are considered to be mediated through 
stimulation of certain type of nuclear receptor known as PPARγ (Sarafidis  et 
al., 2008).  Different  studies have demonstrated that in mice and humans 
treatment with TZDs  causes transcriptional up-regulation accompanied by 
increase endogenous production and secretion of ADN from adipocytes (Yu 
et al., 2002  and Maeda et al., 2002).  TZDs cause an increase in  plasma 
ADN  levels (Pajvani  et al., 2004)  and high molecular weight  ADN  is  the  
principal form of ADN  upregulated by TZDs (Karpichev et al.,  2002). It is 
also evident that TZDs increase plasma adiponectin levels in  obese and 
diabetic animal models, nondiabetic subjects as well as in patients with type 
2 diabetes, by increasing  glucose clearance in skeletal muscle by restraining  
gluconeogenesis in liver, and  improving  insulin sensitivity (Yamauchi et 
al., 2001, Combs et al., 2002  and  Hirose  et al., 2002).  However, it is 
recognised  that  there are PPAR-γ-independent mechanisms by which TZDs  
improve insulin sensitivity. Activation of  AMPK, which is an adipose-
derived factor, ADN, mediates  this  effect (Kahn et al., 2005), and also   
imitates the  metabolic and vascular actions of  insulin  (Han,  et al., 2007)  
Rosiglitazone enhances  AMPK  activity cell lines of  skeletal muscle  
through an increase in the AMP/ATP ratio (Fryer, et al.,  2002). In another 
study,  rosiglitazone treatment re-established  α2AMPK activity in skeletal 
muscle of insulin-resistant  obese Zucker rats  (Lessard, et al., 2006). 
Scherer’s group observed  that ob/ob mice exhibited a significant 
improvement in  glucose tolerance with  rosiglitazone, whereas Adipo–/–
ob/ob mice  remained  glucose intolerant (Nawrocki et al., 2006) which 
suggested that rosiglitazone ameliorated glucose intolerance through ADN-
independent and dependent pathways. In another  trial performed in 64 type 
2 diabetic patients, rosiglitazone treatement  for 6 months resulted  in twice 
the  increase in  plasma  ADN  level  (Yang, et al., 2002)  than  observed in 
normal subjects , while comparable results have been reported for 
pioglitazone (Hirose et al., 2002). This synthetic PPAR-γ agonist, 
rosiglitazone, is reported to increase the serum ADN  level in T2DM.  The 
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activation of PPAR-γ by rosiglitazone increases adipocyte differentiation 
thereby  increasing the  number of small adipocytes which promote body 
weight  apart from  enhancing  adiponectin gene transcription  (Okuno et al., 
1998).  These effects potentially protect diabetic patients from macrovascular  
problems, and thus enable them  to  recover  their insulin sensitivity as well 
as glycemic control  (Yang  et al., 2002).  Expression of  Acrp30 transgene 
results in modulation of lipogenesis  and hepatic gluconeogenesis with a 
consequent reduction in expression of two key genes: PEPCK 
(phosphoenolpyruvate carboxykinase) and SREBP-1c (sterol regulatory 
element-binding protein) in the liver (Shklyaev et al., 2003). Different 
studies also confirmed that  rosiglitazone treatment decreased plasma 
concentrations of glucose, NEFA and triglyceride content, although  body 
weight increased  in  obese Zucker rats (Cai  et al., 2000, Finegood et al., 
2001 and  Reifel et al., 2005),  whereas in animal models  of metabolic 
syndrome, rosiglitazone recovered the metabolic profile and increased 
plasma levels of ADN and its gene expression. (Sharabi, et al., 2007). 
The PPARreceptor-γ ligand, pioglitazone,  is another  oral agent used  
in  the treatment of  T2DM.  Experimental studies have shown show that  
pioglitazone has beneficial effects on insulin resistance (Yki et al.,2004), 
hypertension (Iglarz et al.,2003) and atherosclerosis (Thorp et al., 2007). 
These beneficial effects of pioglitazone on glucose metabolism in patients 
with T2DM  are associated with an increase in the plasma concentration of  
AND (Miyazaki, et al., 2004). Therefore, the pioglitazone-induced 
improvement in insulin resistance is dependent on ADN to improve insulin 
sensitivity  (Kubota,  et al., 2006), and  this  effect is self-regulating for 
reduction in food intake and body weight  increase or activation of PPARγ  
in adipose tissue. (Zhao et al., 2011) 
Troglitazone treatment  is also associated  with  an increase in ADN 
levels in  diabetic,  obese and lean  non-diabetic subjects  (Yu,  et al. 2002). 
In another study, subjects with glucose intolerance  used  troglitazone for 12 
weeks which markedly  increased plasma ADN  levels  in  a dose-dependent 
manner (Maeda,  et al., 2001). 
These PPAR- agonists stimulate the production of adiponectin, which 
promotes fatty acid oxidation and insulin sensitivity in muscle and liver. As a 
result, hepatic glucose production is reduced and muscle glucose use is 
increased (Guan,  et al., 2002). Current evidence suggests close relationship 
between activation of PPARγ and restoration of insulin sensitivity by 
reductions in the stimulation of PI3-K Pathway and also increase in ADN. 
(Tjokroprawiro  2006)  Deficits in AND production  lessen the capability of 
TZDs to recover glucose tolerance (Nawrocki et al., 2006) indicating the 
importance of ADN in the protective effects of TZDs against cardiovascular 
diseases. There are also different reports which confirm that  the activation 
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of PPARγ or a PPARγ agonist, such as TZD, which induces  adipocyte 
differentiation,  improves insulin resistance  (Tsuchida  et al., 2004,  Sharma 
2007, Hunag et al., 2009 and DeFronzo  2010). Besides improving glycemic 
control in subjects  with T2DM, several studies support the notion that TZDs 
have other important actions  on metabolic syndrome, such as significant 
reduction in blood pressure (BP), elevation in high-density lipoprotein–
cholesterol, reduction in triglycerides level  (Lebovitz et al., 2001 and  Stolar 
et al., 2003),  improvement in endothelial function, reduction of intracellular 
Ca2+ content in vascular smooth muscle cells and attenuation of sympathetic 
overactivity (Sarafidis et al., 2006).  
TZDs also have interactions with the renin–angiotensin system 
(RAAS), particularly, rosiglitazone decreases the production of angiotensins 
I and II from human subcutaneous adipose tissue (Harte et al., 2005), 
whereas in other studies TZDs have been observed to downregulate the 
expression of angiotensin AT1 receptor mRNA and  AT1  receptor protein in 
vascular smooth muscle cells  (Takeda  et al., 2000  and  Sugawara,  et al., 
2001). Such actions of TZDs could be attributed  to reports describing their 
ability to blunt angiotensin II-induced vascular smooth muscle cells  
proliferation (Fukuda  et al., 2002). Besides TZDs, which are effective 
exogenous agonists of PPAR-γ (Lehmann, Moore et al. 1995), the AT1  
receptor antagonist telmisartan also acts as  partial agonist of PPAR-γ and 
may potentially be useful in  the treatment of diabetes and  insulin resistance 
in  times to come (Kurtz 2005).  
    Table 1 shows observations pertaining to their effect as reduction in 
blood pressure levels  in  animal studies conducted earlier. 
Table 1: BP: Blood pressure,  SHR: spontaneously hypertensive rats, TZD: 
thiazolidinedione. 
Study TZD treatment Animal model Duration 
Effect 
on BP 
Yoshioka et 
al.1993 Troglitazone Obese Zucker rats 
4 and 8 
weeks  
Fujiwara et al. 
2000 Troglitazone 
Heminephrectomized 
Wistar fatty rats 24 weeks  
     
     Yoshida et al. 
2001 Troglitazone 5/6 nephrectomized SHR 12 weeks  
     Khan et al.   2005 Rosiglitazone Obese Zucker rats 12 weeks 
 
Buckinghamet        
al.1998 Rosiglitazone Obese Zucker rats 
4 and 9 
months  
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1.5 Adiponectin And Angiotensin Receptor Blockers 
Essential  hypertension, the major cause of mortality in developed 
countries  (Ezzati et al., 2002), is linked to additional metabolic irregularities 
like obesity and dyslipidemia, glucose intolerance and  insulin resistance, 
which are collectively classified as the  metabolic syndrome (Eckel  et al., 
2005)  It is considered that hypertension complicated with T2DM results in 
an increased incidence of CVD.  Therefore, treatment of hypertension along 
with  diabetes may be  significant in reducing the risk of   cardiovascular 
complications in subjects with T2DM (Hansson, Zanchetti et al. 1998). 
Metabolic syndrome relates to atherosclerosis and other cardiovascular 
diseases (Gustafson et al., 2007). The activation of  rennin–angiotensin 
system (RAAS) is a general characteristic in patients with the metabolic 
syndrome (Prasad et al., 2004)  
Angiotensin II  apparently reduces adiponectin production. (Ran J et 
al., 2006). However, the molecular mechanisms governing angiotensin II 
signaling reduction in  adiponectin production is still not clear.  There are 
also reports that ACEI and ARBs enhances plasma adiponectin concentration  
in hypertensive patients (Furuhashi et al., 2003 and  Lely et al., 2007), 
whereas sympathetic activation restrains ADN expression through β 
adrenergic mechanisms  (Delporte et al., 2002, and Imai et al., 2006). One 
pathway underlying ADN reduction is that via inflammatory cytokines, eg, 
TNF-α, which causes transcriptional suppression and inhibition of 
adiponectin secretion (Maeda  et al., 2001). 
ARBs, are now  considereed as first line of treatment for hypertensive 
individuals  with T2DM.  Apart from their antihypertensive activity, they 
also have metabolic actions and improve insulin resistance and enhance 
serum AND levels  (Furuhashi et al., 2003  and  Kurtz et al., 2006)  They  
play pivotal role in cardiovascular, metabolic abnormailities like 
hyperlipidemia, through AT1 receptor-mediated signaling  (Cooper et al., 
2007 and Perkins et al., 2008). These receptor blockers are characterizsed  as  
a class of orally active and effective antihypertensive drugs in diabetic and 
hypertensive individuals (Adler 2002). They also act as fractional PPARγ 
agonists  (Drazen et al., 2007).             
Adiponectin  levels are higher   in patients receiving   long-term ARB 
therapy, indicating that ARBs decrease arterial stiffness by increasing  serum 
ADN concentration and is independent of their effect on BP. One possible 
mechanism is that ARB can cause an increase in adipogenes which results in 
a larger capacity for ADN production, as in vitro studies have proved that 
angiotensin II distinctly slow down adipogenic differentiation of human 
adipocytes through angiotensin AT1 receptor (Sharma et al., 2002). Studies 
in animlas established the function of angiotensin II signaling in diabetes and 
insulin resistance  (Dahlof  et al., 2002),  whereas Agata and colleagues  
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observed that long-term blockade of the (RAAS) could  be  appropriate 
treatment for averting  increased arterial stiffness and lessening chances for 
cardiovascular complications, and  this  reduction  in arterial stiffness after 
ARB treatment could be due to an increase in  serum  ADN  concentration 
(Agata  et al., 2004). The  evaluation of antihypertensive drugs for their 
effect on regulation of ADN, ACE inhibitors and ARBs  treatment has been 
shown to enhance ADN levels compared to other classes of antihypertensive 
drugs. RAAS blockers enhance plasma adiponectin levels to a greater extent 
than doxazocine, amlodipine and metoprolol regimens ( Yilmaz et al., 2007)  
Eenhanced ADN levels recover endothelial function and insulin sensitivity 
through various  mechanisms (Koh  et al., 20005).  Most common ARBs are 
not strong PPARγ activators which only occurs when given in high 
concentrations. There are also findings demonstrating that  some AT1 
receptor blockers (ARBs) have an agonistic action on  nuclear PPARγ 
receptors (Benson et al.,2004,  Schupp, et al., 2004,  Kurtz., 2006,  Iwai, et 
al ., 2007 and  Y. Tomono et al., 2008)                               
Among ARBs, there is clear order of potency. Telmisartan is the most 
powerful and the only ARB to exhibit  an effect at physiologically 
achievable plasma concentrations. Adiponectin is linked with glucose 
sensitisation and is modulated  by activation of AT1, AT2 receptors and  
PPARγ agonists which are considered to stimulate adipocyte differentiation, 
as the  breakdown  of adipocyte differentiation  is associated with  T2DM  
(Kintscher and Unger 2005).  In recent times, ARBs (irbesartan, telmisartan) 
have been shown to be ligands of the PPARγ receptor. Telmisartan also 
stimulates adiponectin protein expression, whereas the non-PPARγ-
activating ARB  like eprosartan does not express this effect. The PPARγ 
antagonist GW9662 significantly blocked irbesartan-induced AND  
expression (Clasen et al., 2005). Telmisartan, acts as an incomplete agonist 
of PPARγ and manipulates the expression of PPARγ target genes involved in 
lipid and carbohydrate metabolism, ultimately lowering insulin, triglyceride 
and  glucose levels in rats  on elevated  carbohydrate  and  fat diets  (Stephen 
et al., 2004).  Irbesartan and telmisartan act as binding/dissociation 
discriminatory cofactors with a link between selective gene regulation  and 
ligand-induced conformational changes of PPAR- γ at the molecular level, 
and thus may activate  specific metabolic effects  (Berger., 2003,  Wang, et 
al .,2003 and  Guan et al., 2005).  Furthermore,  the stimulatory effect of 
ARBs on PPARγ has been  studied  in a cell-free system, signifying the 
binding of  blockers with PPARγ (Erbe, et al., 2006). The influence  on the 
perfection of  metabolic profile confirmed by telmisartan and the inverse 
correlation between ADN concentration and B.P could  be partly due to its  
partial PPARγ  agonistic activity  (Negro et al., 2006).  Analysis of PPARγ  
protein conformation using protease protection demostrated that irbesartan 
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and telmisartan interacted with the receptor, thereby producing  
conformational change which were different compared to those induced by 
pioglitazone  (Schupp., 2005).  In another recently conducted  study  by 
Shiota, this group also observed that telmisartan acted through a  
PPARgamma-independent pathway, but  to some extent exerted  its effects 
through a direct action on skeletal muscle AMPK/SIRT1 signalling pathways  
(Shiota, et al. 2012) .  
In vivo, irbesartan administration  increased the  DNA-binding 
activity of PPARγ in white adipose tissue (WAT) of atherosclerotic mice. It 
increased adipocytes, and lessened WAT  weight  and increased  mRNA 
expression of PPARγ in WAT.  It can be assumed that a PPARγ agonist 
induces adipocyte differentiation, thereby, causing adipocytes of smaller size  
and increasing insulin sensitivity (Tsuchida et al., 2005),  whereas  treatment  
with  angiotensin II in rats decreased plasma ADN concentration via  ATR1 
receptor signalling  (Ran J  et al., 2006).  These explanations suggest the 
possibility that ARBs show  partial agonistic activity of PPARγ and through 
this mechanism could improve adipocyte differentiation. In addition, the 
ARBs losartan and candesartan enhance adiponectin plasma levels in 
essential hypertensive individuals (Furuhashi,  et al. 2003, Watanabe et al., 
2006 and Koh, Quon et al. 2004). 
Apart from their role in the CVS,  ARBs have been acknowledged as 
controller of lipid and glucose  metabolism in adipose tissue. Clinicians have 
observed that AT1R antagonism lessen the risk for T2DM  as compared to  
other  antihypertensive therapies  (Scheen 2004). Humans and rodents 
studies have shown an improvement in insulin sensitivity when treated with 
AT1 blockers (Benson et al., 2004, Negro et al., 2006, Aksnes, et al., 2007, 
Nishimura, et al., 2008 and  Rong et al., 2010). Moreover, Ang II is believed  
to  antagonize insulin signaling in liver and skeletal muscles (Olivare et al. 
2009). Furthermore Ang II contributes to the pathogenesis of insulin 
resistance and myocardial remodeling in pioglitazone treated subjects 
through an  ADN  dependant  mechanism  (Li, et al., 2010).                               
The usefulness of Azilsartan  in  treatment  of  the  metabolic 
syndrome,  the insulin-sensitizing effect  is  self-regulating of increase in 
body weight and  decreases in food intake or of  the activation of adipose 
PPARγ  in  obese Koletsky rats  (Zhao,  et al. 2011). In another study,  Iwai, 
observed that in normotensive KK-Ay mice azilsartan was more effective as 
compared to candesartan in reducing plasma concentrations of fatty acids 
and glucose, enhancing adipose expression of PPAR-γ with its target  AND 
genes, besides  decreasing adipose tissue weight  and  size, without altering 
B.P or plasma insulin concentrations (Iwai, Chen et al. 2007).  Other ARBs  
like efonidipine, ramipril and candesartan enhance  ADN evels and  insulin 
sensitivity in subjects  without body mass index change (Koh  et al., 2005, 
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 Koh et al., 2006 and  Koh, et al. 2007). Adding together  ramipril and 
candesartan  have direct effects to exhance  insulin-stimulated glucose 
uptake and promote adipogenesis (Arya  et al., 2002)  and induce PPAR-γ 
activity which aides differentiation of adipocytes (Schupp et al., 2004). 
Agents which block RAAS,  candesartan and temocapril, increased ADN  
levels with associated improvements in insulin sensitivity without affecting 
adiposity (Furuhashi , et al., 2003). The system, through which these drugs 
enhance  ADN,  is improvement  in insulin sensitivity and  modification in  
adipocyte differentiation whereas quinapril enhances the expression of ADN 
in T2DM patients ( Hermann et al., 2006), and ramipril prevents the  
commencement of  diabetes  (Bosch  et al., 2005).                                                    
Kidneys secrete renin  and mediate the production of angiotensin II 
from angiotensinogen.. Adiponectin production is  inhibited by  angiotensin 
II, whereas Angiotensin II receptor blockers exhibit antidiabetic like  activity 
and B.P  control via  AND which stimulates the production of nitric oxide 
(NO), and  regulates blood pressure (Wang and Scherer 2008). In a recent 
observation, irbesartan activated PPARγ in WAT of atherosclerotic mice 
which was associated with an improvement of adipose tissue function in  
atherosclerosis and adipocyte differentiation  (Iwai, et al. 2011). The role of 
ADN and mechanism of action of TZDs and ARBs through AND in diabetes 
and hypertension is shown in Fig 2. 
 
Fig 2: Role of adiponectin through ppar gamma in diabetes and hypertension 
Mechanism of action of TZDS and ARBs directly and through adiponectin 
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1.6 Conclusion And Future Directions 
We are living in a world where the prevalence of T2DM and 
hypertension are increasing at a rapid pace and their alarming  increase 
compels the scientists to make novel and  effective remedies for both these 
diseases.  There are reports which are providing us with the latest figures 
regarding these co-morbidities associated with metabolic syndrome from 
developed and third world countries. PPAR-γ  is a universal pharmacological 
objective as it plays its significant role as a negotiator for both 
thiazolidinediones as well as ARBs, particularly in improving insulin 
sensitivity, thereby offering protection against T2DM and the reduction in 
blood pressure through an increase in adiponectin level.  TZDs  (antidiabetic 
therapeutic agents), whose primary target is PPARγ, require ADN as their 
mediator for the expression of  their desired  effects, but  there are serious 
concerns regarding thier cardiovascular safety  (Drazen JM et al., 2007).  
Several studies have proven that treatment with  antihypertensive drugs like 
ARBs enhance ADN concentration  with PPAR-γ as their mediator and thus 
exert multiple effects, like B.P control, antidiabetic activity, and  
cardioprotection.  There is  no doubt ADN,  as a guardian angel, may have 
many beneficial effects to its credit, but there is another side of the coin  that   
the  cost effectiveness of  the compound and  its  admistration  as therapeutic 
agent, urges us to find alternate and safe therapeutic strategies. TZDs have 
their own limitations. Angiotensin receptor blockers (ARBs) only address the 
issue in an effective manner if the goal/purpose is only to activate PPAR-γ 
receptors and ultimately increase ADN concentrations in body, from  
bifunctional treatment point of view. Adiponectin has become an important 
potential focus for  the development of  therapeutic compounds, but the size 
of  the  molecule and its glycosylation requirement presents  difficulty in the 
synthesis of this hormone. Different corporations have stopped their efforts 
for secretion and   of  ADN  through adipose tissue  (George L Blackburn., 
2010). It is also controversial whether ADN bears a risk factor for 
cardiovascular diseases (CVD).  However,  there can be  further exploration 
for the presence of  ADN  in  natural sources, or  for  compounds which have  
ADN  as part of  their molecular structure.  Further studies on these lines will 
help us gain a better perceptive of these findings and thus  develop novel as 
well as safer therapeutic compounds. 
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